Biotech Values

[winchem21]

AMD Data update minus high/low readings.

Throwing out the high and low results for each of the AMD trials, here are the averages from the four remaining patients for the data that have been reported on GENR's site.

Date  Mex  40mgst 40mg2nd 10mg 
 Wk3	6.5	6.9	4.3	0.8 
 EOT	8.8	7.8	7.1	2.7 
 2Mon	6.9	2.8	2.9   -1.9  
 4Mon  5.7   -1.5   3.9   -2.0

For the 4 median patients taking 40 mg doses and combining both eyes, there was an average dropoff of about 1 letter per month between 2 and 4 months. This is approximately the same rate of vision loss as shown for untreated patients in an earlier slide.

The 20 mg data and the 10mg 2nd eye data have not been reported to date. Perhaps these missing data are even less compelling.....given GENR's need to finance phase III trials.

wc21